NewsBenzingaAdagene在一项1期研究中为首位患者给药,评估muzastotug联合Incyte的TGFβR2×PD-1双特异性抗体INCA33890用于微卫星稳定型结直肠癌患者 Adagene在一项1期研究中为首位患者给药,评估muzastotug联合Incyte的TGFβR2×PD-1双特异性抗体INCA33890用于微卫星稳定型结直肠癌患者 Benzinga 2026.10.28 11:05 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story